Popular diabetes drugs, including Avandia and Actos, may increase the risk of fracture, according to research from the University of Michigan.
From a large prospective database of patients with diabetes, investigators compared 786 patients with fractures and 2657 matched patients without fractures. Women with fractures were significantly more likely than controls to be taking thiazolidinediones (TZDs), a class of diabetes drug that includes rosaglitazone (marketed by GlaxoSmithKline as Avandia) and pioglitazone (marketed by Takeda as Actos). Men with fractures were more likely than controls to be taking TZDs in combination with loop diuretics.
The findings are slated for publication in the October issue of the Journal of Clinical Endrocrinology & Metabolism.